0
Clinical Crossroads | Conferences With Patients and Doctors| Clinician's Corner

Management of Active Crohn Disease

Adam S. Cheifetz, MD
JAMA. 2013;309(20):2150-2158. doi:10.1001/jama.2013.4466.
Text Size: A A A
Published online

Importance Treatment of Crohn disease is rapidly evolving, with the induction of novel biologic therapies and newer, often more intensive treatment approaches. Knowing how to treat individual patients in this quickly changing milieu can be a challenge.

Objective To review the diagnosis and management of moderate to severe Crohn disease, with a focus on newer treatments and goals of care.

Evidence Review MEDLINE was searched from 2000 to 2011. Additional citations were procured from references of select research and review articles. Evidence was graded using the American Heart Association level-of-evidence guidelines.

Results Although mesalamines are still often used to treat Crohn disease, the evidence for their efficacy is lacking. Corticosteroids can be effectively used to induce remission in moderate to severe Crohn disease, but they do not maintain remission. The mainstays of treatment are immunomodulators and biologics, particularly anti–tumor necrosis factor.

Conclusion and Relevance Immunomodulators and biologics are now the preferred treatment options for Crohn disease.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

Figures

Place holder to copy figure label and caption
Figure 1. Differences in Disease Characteristics Between Crohn Disease and Ulcerative Colitis
Graphic Jump Location
Place holder to copy figure label and caption
Figure 2. Helical Computed Tomography Imaging of the Patient's Abdomen and Pelvis
Graphic Jump Location

Coronal computed tomography views show slightly increased enhancement in the mucosa of the terminal ileum near the ileocecal valve with areas of slight wall thickening and mural stratification with predominantly intramural fat (yellow arrowheads), as well as feculent luminal contents (pink arrowhead). More proximal loops of ileum are slightly dilated (blue arrowheads).

Place holder to copy figure label and caption
Figure 3. Biopsy of the Patient's Ileal Mucosa
Graphic Jump Location

Biopsy demonstrating replacement of the normal intestinal-type epithelium, composed of goblet cells and enterocytes, with mucous-type glands normally seen in the gastric pylorus (hematoxylin-eosin stain, original magnification ×400). This histologic feature of pyloric gland metaplasia is indicative of chronic injury often seen in the terminal ileum of patients with Crohn disease.

Tables

References

CME


You need to register in order to view this quiz.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 5

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles
Managing inflammatory bowel disease in adolescent patients. Adolesc Health Med Ther 2014;5():1-13.
Colonoscopic perforation in inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2013;9(9):573-83.
Jobs
brightcove.createExperiences();